Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation

International Journal of Cardiology

Volumn 87, Issue 2-3, 2003, Pages 121-128

  Khan, Ijaz A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Cardioversion; Class IC antiarrhythmic drugs; Flecainide; Sodium channel blocker; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLECAINIDE; PLACEBO; PROPAFENONE;

ADVERSE DRUG REACTION; CARDIOVERSION; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HUMAN; LITERATURE; LOADING TEST; PRIORITY JOURNAL; QRS COMPLEX; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; VERTIGO; VISUAL DISORDER;

EID: 0037307438     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00467-9     Document Type: Article

References (36)

1. Gardner M.J., Gilbert M. Heart rate control in patients with atrial fibrillation. Can J Cardiol. 12:1996;21A-23A.
2. Cuddy T.E., Connolly S.J. Atrial fibrillation and atrial flutter. Can J Cardiol. 12:1996;9A-11A.
3. Shettigar U.R., Toole J.G., Appunn D.O. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation and flutter. Am Heart J. 126:1993;369-374.
4. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicenter trial in 239 patients. Eur Heart J. 18:1997;649-654.
5. Wattanasuwan N., Khan I.A., Mehta N.J., et al. Acute ventricular rate control in atrial fibrillation. i.v. combination of diltiazem and digoxin vs. i.v. diltiazem alone. Chest. 119:2001;502-506.
6. Daoud E.G., Marcovitz P., Knight B.P., et al. Short-term effects of atrial fibrillation on atrial contractile function in humans. Circulation. 99:1999;3024-3027.
7. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 92:1995;1954-1968.
8. Franz M.R., Karasik P.L., Li C., Moubarak J., Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 30:1997;1785-1792.
9. Gallik D., Altamirano J., Singh B.N. Restoring sinus rhythm in patients with atrial flutter and fibrillation: pharmacologic or electrical cardioversion. J Cardiovasc Pharmacol Ther. 2:1997;135-144.
10. Levy S. Restoring sinus rhythm in atrial fibrillation: electrical or pharmacological cardioversion. Ann Noninvasive Electrocardiol. 3:1998;109-114.
11. Golzari H., Cebul R.D., Bahler R.C. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 125:1996;311-323.
12. Costeas C., Kassotis J., Blitzer M., Reiffel J.A. Rhythm management in atrial fibrillation with a primary emphasis on pharmacological therapy. Pacing Clin Electrophysiol. 21:1998;742-752.
13. Miller M.R., McNamara R.L., Segal J.B., et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 49:2000;1033-1046.
14. Singh B.N., Mody F.V., Lopez B., Sarma J.S. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol. 84:1999;161R-173R.
15. Biffi M., Boriani G., Bronzetti G., Capucci A., Branzi A., Magnani B. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart. 82:1999;176-182.
16. Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis. 44:2001;121-152.
17. Suttorp M.J., Kingma J.H., Jessurun E.R., Lie-A-Huen L., van Hemel N.M., Lie K.I. The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 16:1990;1722-1727.
18. Goy J.J., Maendly R., Grbic M., Finci L., Sigwart U. Cardioversion with flecainide in patients with atrial fibrillation of recent onset. Eur J Clin Pharmacol. 27:1985;737-738.
19. Peters F.P., Braat S.H., Heymeriks J., Wellens H.J. Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide. Neth J Med. 53:1998;93-96.
20. Capucci A., Villani G.Q., Piepoli M.F., Aschieri D. The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Curr Opin Cardiol. 14:1999;4-8.
21. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 37:2001;542-547.
22. Kingma J.H., Suttorp M.J. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol. 70:1992;56A-61A.
23. Capucci A., Lenzi T., Boriani G., et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 70:1992;69-72.
24. Capucci A., Boriani G., Botto G.L., et al. Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 74:1994;503-505.
25. Boriani G., Biffi M., Capucci A., et al. Conversion of recent onset atrial fibrillation to sinus rhythm: effect of different drug protocols. Pacing Clin Electrophysiol. 21:1998;2470-2474.
26. Villani G.Q., Rosi A., Piepoli M., et al. The efficacy of oral treatment with flecainide for paroxysmal atrial fibrillation: correlation with plasma concentration. G Ital Cardiol. 20:1990;564-568.
27. Botto G.L., Bonini W., Broffoni T., et al. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol. 17:1994;2114-2117.
28. Crijns H.J., van Wijk L.M., van Gilst W.H., Kingma J.H., van Gelder I.C., Lie K.I. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J. 9:1988;634-638.
29. Alp N.J., Bell J.A., Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 84:2000;37-40.
30. Tjandra-Maga T.B., Verbesselt R., Van Hecken A., Mullie A., De Schepper P.J. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. Br J Clin Pharmacol. 22:1986;309-316.
31. Lie-A-Huen L., Proost J.H., Kingma J.H., Meijer D.K. Absorption kinetics of oral and rectal flecainide in healthy subjects. Eur J Clin Pharmacol. 38:1990;595-598.
32. Hage K., Buhl K., Fischer C., Knebel N.G. Estimation of the absolute bioavailability of flecainide using stable isotope technique. Eur J Clin Pharmacol. 48:1995;51-55.
33. Nappi J.M., Anderson J.L. Flecainide: a new prototype antiarrhythmic agent. Pharmacotherapy. 5:1985;209-221.
34. Johnston A., Warrington S., Turner P. Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol. 20:1985;333-338.
35. Santinelli V., Arnese M., Oppo I., et al. Effect of flecainide and propafenone on systolic performance in subjects with normal cardiac function. Chest. 103:1993;1068-1073.
36. Josephson M.A., Ikeda N., Singh B.N. Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol. 53:1984;95B-100B.